What are the most promising second-generation TKIs, and will they find a niche in NSCLC?
A number of second-generation agents appear promising, including compounds that are irreversible dual kinase inhibitors of both EGFR and HER2. At this point, it is unclear which of these agents will prove to be the most active or useful in lung cancer. It is unlikely that these compounds will see the greatest use as second-line agents but rather as potentially superior first-line drugs for mutation-positive patients. It is not at all clear if these TKIs will have any role in the treatment of EGFR wild-type patients.
